Akari Therapeutics plc ADR (0.01 USD) (AKTX) insider trading

{
  "status": "OK",
  "results": [
    {
      "tickers": [
        "AKTX"
      ],
      "issuer_cik": "0001541157",
      "owner_cik": "0001843601",
      "accession_number": "0001493152-26-047456",
      "form_type": "4",
      "filing_date": "2026-10-16",
      "period_of_report": "2026-08-18",
      "issuer_name": "Akari Therapeutics Plc",
      "issuer_trading_symbol": "AKTX",
      "owner_name": "Patel Sandip I",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "derivative",
      "record_type": "transaction",
      "security_title": "Pre-Funded Warrant to Purchase ADSs",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-10-14",
      "transaction_code": "M",
      "equity_swap_involved": false,
      "transaction_shares": 6186,
      "transaction_price_per_share": 16.16,
      "transaction_acquired_disposed": "D",
      "shares_owned_following_transaction": 0,
      "transaction_value": 99965.76,
      "exercise_price": 0.0004,
      "underlying_security_title": "American Depositary Shares representing Ordinary Shares",
      "underlying_security_shares": 6186,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F9",
          "description": "On December 16, 2025, the Reporting Person and the Issuer entered into a securities purchase agreement, pursuant to which the Issuer issued to the Reporting Person (i) pre-funded warrants (the \"Private Placement Pre-Funded Warrants\") to purchase up to 6,186 ADSs, at a purchase price of $16.16 per Private Placement Pre-Funded Warrant, and (ii) warrants to purchase up to 6,186 ADSs."
        },
        {
          "id": "F10",
          "description": "The combined purchase price per one pre-funded warrant and accompanying warrant was $16.16."
        },
        {
          "id": "F6",
          "description": "The pre-funded warrants became exercisable upon shareholder approval, which was obtained on March 2, 2026."
        },
        {
          "id": "F7",
          "description": "The pre-funded warrants remain exercisable until fully exercised."
        }
      ]
    },
    {
      "tickers": [
        "AKTX"
      ],
      "issuer_cik": "0001541157",
      "owner_cik": "0001702447",
      "accession_number": "0001493152-26-047453",
      "form_type": "4",
      "filing_date": "2026-10-16",
      "period_of_report": "2026-08-18",
      "issuer_name": "Akari Therapeutics Plc",
      "issuer_trading_symbol": "AKTX",
      "owner_name": "Patel Samir Rashmikant",
      "is_director": true,
      "is_officer": false,
      "is_ten_percent_owner": false,
      "is_other": false,
      "security_type": "derivative",
      "record_type": "transaction",
      "security_title": "Stock Option (Right to Buy)",
      "transaction_timeliness": "O",
      "aff_10b5_one": false,
      "transaction_date": "2026-08-18",
      "transaction_code": "A",
      "equity_swap_involved": false,
      "transaction_shares": 30000,
      "transaction_price_per_share": 0,
      "transaction_acquired_disposed": "A",
      "shares_owned_following_transaction": 30000,
      "transaction_value": 0,
      "exercise_price": 7.899,
      "expiration_date": "2036-08-18",
      "underlying_security_title": "American Depositary Shares representing Ordinary Shares",
      "underlying_security_shares": 30000,
      "not_subject_to_section_16": false,
      "direct_or_indirect": "D",
      "footnotes": [
        {
          "id": "F4",
          "description": "On August 18, 2026, the Reporting Person was granted an option to purchase 30,000 ADSs. This option grant is subject to forfeiture if Shareholder Approval is not obtained. The option will vest with respect to 4.17% for each one-month anniversary of August 18, 2026 that has elapsed before the date of Shareholder Approval. The remainder of the option grant will vest in equal, monthly installments beginning on the 18th day of the month subsequent to the month where Shareholder Approval was obtained until fully vested on the two-year anniversary of August 18, 2026, subject to the Reporting Person's continued service with the Issuer on each such vesting date."
        }
      ]
    }
  ]
}

// trimmed to 2 results

The response includes every Form 4 record; this page keeps open-market purchases and sales on common stock and removes duplicate joint-filer rows.